Search alternatives:
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1361
-
1362
-
1363
-
1364
-
1365
-
1366
Magnetic field setups in zero field (a) and vertically alternating field (b).
Published 2022Subjects: -
1367
-
1368
-
1369
Multivariable Linear Regression Model of the Residents P-V Fit score<sup>a</sup>.
Published 2025Subjects: -
1370
-
1371
-
1372
-
1373
Effects of FE and RUD wrist postures on the mean shape signature phase shift within each quartile.
Published 2022Subjects: -
1374
Exposures to PM<sub>2.5</sub>, PM<sub>10</sub> and Nitrogen dioxide.
Published 2024“…A sizeable proportion also had annual mean exposures that surpassed the WHO PM<sub>10</sub> (14.8%) and nitrogen dioxide (63%) recommended thresholds. …”
-
1375
-
1376
Mean SARS-CoV-2 viral load log 10 between groups.
Published 2024“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
-
1377
-
1378
-
1379
-
1380